Phase I/II study: on the toxicity and effects of combining the p53 synthetic long peptides vaccine with either Imiquimod or Interferon-alfa to induce polarized p53-specific immunity in patients treated for colorectal cancer.
Phase of Trial: Phase I/II
Latest Information Update: 24 Mar 2012
At a glance
- Drugs Imiquimod (Primary) ; ISA 102 (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacodynamics
- 06 Aug 2011 New trial record